NFL Biosciences :
Availability of the Half-Year Financial Report as of June 30, 2021
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of dependencies and addictions, announces that it has made available to the public and filed with the Autorité des Marchés Financiers (AMF) today, Monday October 4, 2021, its Half-Year Financial Report as of June 30, 2021.
The Half-Year Financial Report can be viewed on the company’s website at: https://fr.nflbiosciences.com/investors “Documentation” section.
About NFL Biosciences
NFL Biosciences is a biopharmaceutical company based in the Montpellier region whose most advanced botanical drug candidate is a smoking cessation aid. Called NFL-101, this natural product, extracted from standardized tobacco leaves and devoid of nicotine, is protected by two families of patents. NFL Biosciences intends to offer smokers who wish to quit a natural, safe, long-term effective, short administration and personalized alternative.
Beyond NFL-101, NFL Biosciences has plans to develop botanical drugs for the treatment of cannabis use disorders and alcoholism.
NFL Biosciences shares are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). The company is qualified as an “Innovative Company” eligible for investment by FCPIs.
More information on www.nflbiosciences.com
Bruno Lafont – firstname.lastname@example.org – 04 11 93 76 67
Calyptus Agency – email@example.com – 01 53 65 68 68